{"name":"Escient Pharmaceuticals, Inc","slug":"escient-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"EP547","genericName":"EP547","slug":"ep547","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"EP547","genericName":"EP547","slug":"ep547","phase":"phase_2","mechanism":"EP547 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPWkhmLWpqOUhBRTVmajZYU0FHNE5LdGRSY1dYTjRKM29oT1FUemRrWmFQakdQOTdYRXJUVDFjWjhTZkIzeE9RODZXbmIyQWgyamVlcldERVZsbkw5YnJJMTI0dUNqQzBGNU5FTmJMZjdPbTBCSVc3R1VYMUNXZ0pjTHRveVJQNEhsSzBIc1RJYnNwMVpsRWUtekJweFM2blVzclE?oc=5","date":"2026-01-22","type":"pipeline","source":"BioPharma Dive","summary":"BioMarin vets form Mendra to ‘modernize’ rare disease drug development - BioPharma Dive","headline":"BioMarin vets form Mendra to ‘modernize’ rare disease drug development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9hRWh3TFA2VkkxMk5KLVNZbmE0ekhuT2QxRkZha1czeTN5QlRsQ3NkcnVDallVWXQxSk1HQjBfMkd3SU5SRlZmVi1WaDNFejNBQWZr?oc=5","date":"2026-01-22","type":"pipeline","source":"FirstWord Pharma","summary":"Ex-BioMarin execs launch Mendra with $82M to 'modernise' rare disease R&D - FirstWord Pharma","headline":"Ex-BioMarin execs launch Mendra with $82M to 'modernise' rare disease R&D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNYUpQcnBPY21uM1c1RXZJem9YZENValE2QUdILWprM3ZTRDlUR0ZTc1BQUHJGYVF3ZFFJMFp0ZkFNREN3czJ2WDhYajB1T3JwSVg0aHg4RG9XUFh3bTZDY0g2SktwRjZicm1Za1ZucnB5QjNPMEpmM1dMYkw2R1BodkoxQ2pKb3dHSlZ1dWJNZ2h3akQzVWVXcTg3MDlLWWZnZjRadlhxeFhpbWNY?oc=5","date":"2025-08-04","type":"deal","source":"Fierce Pharma","summary":"Incyte's new CEO pledges 'fresh look' at business, outlines dealmaking strategy - Fierce Pharma","headline":"Incyte's new CEO pledges 'fresh look' at business, outlines dealmaking strategy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPQUkzM0NYWnRNZDlvMEtsNmZfLW1IVXhBWGo4QjNlOVpnd3d0Q0dQREYwZ1o5bXg1ckdRbFNTeTkwUm9KbExGUVdVYnJnMENyYUl6QkxvU3JxMFZUX2VCM0NjVE5KMk9ZdUNPVThZd18wZTJVM3pNbzdITFQzQVhxb2ROZWI5WThodUlRWXhoRHZ6dHBteEotaWZ4S081VjFMSExsaE93?oc=5","date":"2024-11-19","type":"pipeline","source":"BioSpace","summary":"Incyte’s $750M Escient Bet Flops as Skin Disease Assets Stumble - BioSpace","headline":"Incyte’s $750M Escient Bet Flops as Skin Disease Assets Stumble","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNTEFFbndvR3JONUM0ejRWRkVrTEltN2s5SUQyZWRLZU1RTkdaRzdzN3RPNGlWUUZNY2luc3lUSW1McnVHYWRWbXFuMHU5eUl2NXhIamo5d3Bwd0VUc1lReXF2Zmhwb1FzaWZRUlBpX2xUN3pLU1RzWHJReXhUaWxRR2ppbHdzczN5R2ttZDVIWEZNT0NEdFFDMUltMA?oc=5","date":"2024-11-19","type":"deal","source":"BioPharma Dive","summary":"Incyte sinks on setback for drugs acquired in $750M buyout - BioPharma Dive","headline":"Incyte sinks on setback for drugs acquired in $750M buyout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE0zQXM4TUdPcHN6dVR6UzRGc0VwUjhaNkdMNDY2TENveEJSa1VZOFJoNlN5ekExcVFrUkRidmtKaWMzQjhURXlFeXM5YUV5SE5odmNmWkNyTWY3V0c4bldmSXE2dGRqOEswaFlOb3JhNGc3UdIBekFVX3lxTE1sMnFGcjVpVjhlTnFueXViQmticVlKaThHX0xQYnNPQXhVbFh2NnUweWVseUxORC10TVladWVMcnV6T2RFV2FQaTNlOEhHZHI5SmowZ09uRDR0ZjlGVUVmeFhobXYzUllfVVVOM19MV1pFSFlDM0U3Wm9B?oc=5","date":"2024-06-03","type":"deal","source":"Delaware Business Times","summary":"Incyte closes $750M deal for Escient Pharmaceuticals - Delaware Business Times","headline":"Incyte closes $750M deal for Escient Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOZlJZVHZoRzhtNHpHM2ZpbFo5dkpPUzZJT1NFS3cyT0N0bGViY2hxdjRXbEk5bXd4U1NTb3kxQkVsQUk4VWdBQ3NmX012LTJJMkZDZVk5QWhLYUk1eVEtczJvZnVWZWY2a3lnMUhFWHFUWURoT1dPTTl1YlpMSUR5NnVGOE02Tnd6QmxzaDUwTDBwbXlUbUtTZnpCNkpZemE4c2Y1SU9rTzJTX3Y4?oc=5","date":"2024-05-31","type":"pipeline","source":"The Business Journals","summary":"Incyte completes $750 million acquisition of pharma firm - The Business Journals","headline":"Incyte completes $750 million acquisition of pharma firm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQZFg5cW5IcS1BWFAySEJ4X3NDdmtKVWs5dkVBcTJtVlRqRWl4RjRuc25sblZWTThUR0ZWTDdYZk1ZU0xIR25qQTNZNnBHOVQ1eW84RThlT3R6enJhOWo0MVhSalR3LTZYdTZlbDdoUnktNHdYY01PLVhwMnFzanJZX2M4anQ?oc=5","date":"2024-04-24","type":"deal","source":"Pharmaceutical Technology","summary":"Incyte signs deal to acquire Escient Pharmaceuticals - Pharmaceutical Technology","headline":"Incyte signs deal to acquire Escient Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxOcU9DZC1TUzVndHR0YUpUVlIxUEdsejE1UWpPbGNLdTEtemJhalZtU1pPZFJCMjNGVjNtaUZ3aElZMkNvODV2bU90cDU1SnZqdnI2bEtfZlZEbllmVDRtN19IUHlnTTRfWWJJQnA1RzFvVjg1M2k2UW5LUUdOSFpERGozSnhNMTZXY3pOMGlYa0h4bDhFM0JySnNOSUVVYlp6d0s0dFd5ZmVHVTcxMXQ0OUQ0cjB1eXJSQjBJTEdiZ2I4cHhLTGRWSXp1aGU2cW5TQWRLbV9McEVCM1Zxd1NMNUoyTVFNdDVKMzdRZGk2Y1FXMEp3UHdTSGtYWlJ4VVU?oc=5","date":"2024-04-23","type":"pipeline","source":"businesswire.com","summary":"Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists - businesswire.com","headline":"Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNTzRtSTcycE1VN3lGalAxejlTdlQ1czBJb2RMdGtGNWJRWlRXTUJNMjR5V3BzbXIzV3dGYmROM3kyRDhiRmdnZnhuVm5KdXZCaDFXV2RnN0tOWlY4M3ZJSVViVThLNHRaclB0MkROdXVPOTNtbWJoR1pKVFNiMUNPQlVldC1oQkgtU2NLb29n?oc=5","date":"2024-04-23","type":"deal","source":"Contract Pharma","summary":"Incyte Acquires Escient Pharmaceuticals - Contract Pharma","headline":"Incyte Acquires Escient Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQcmtUQktpU1U4b0xISkpyMjNnWUxyVjAtcjhjWVY3VTNUU0kwUnpweHZtZ0FaSktmN2tNbVBUdzVJUTZKTGRHOExtU0xlVy1YSlNTekpoWldNMFljdjYyT0NQcHN6UzBEd0w2WUE0NEJaeWlxZ3NLUXdBa0tYNElTejlvc2VTVldaNEcwZktXWUVuRHlwLUFkeU0tZzhfanBZS2c4U2pn?oc=5","date":"2024-04-23","type":"deal","source":"fiercebiotech.com","summary":"Incyte, fresh off gaining MorphoSys drug, buys Escient for $750M - fiercebiotech.com","headline":"Incyte, fresh off gaining MorphoSys drug, buys Escient for $750M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQMU9pWXl3SFlieEFZTllueUN6RzZVeWNabFlVQjNCZENBTGNRRTRydVlhVHdIbnBSbG1QaWZPa25FaGNJNTdEbUN1Z1BQTzh3TnIxRURGbEpqMGZrWFpKUTZoeHBjbkpwdEgwVVFUNlQ3VjJEWnBiOEV5cXNlXzUtLWFWc2pmeUQxaVM4TTRfdDlGMVZJYnF2TXNkdUpoM28?oc=5","date":"2024-04-23","type":"pipeline","source":"Medical Marketing and Media","summary":"Incyte bolsters derm pipeline with $750M acquisition of Escient - Medical Marketing and Media","headline":"Incyte bolsters derm pipeline with $750M acquisition of Escient","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}